Alumis (ALMS) Projected to Post Earnings on Wednesday

Alumis (NASDAQ:ALMS) is anticipated to post its quarterly earnings results before the market opens on Wednesday, February 26th. Analysts expect Alumis to post earnings of ($1.40) per share for the quarter.

Alumis Trading Up 1.4 %

ALMS stock opened at $5.24 on Tuesday. Alumis has a 12-month low of $4.74 and a 12-month high of $13.53. The company has a 50 day moving average of $7.11 and a two-hundred day moving average of $9.67.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the stock. Baird R W upgraded shares of Alumis to a “strong-buy” rating in a research report on Thursday, October 31st. HC Wainwright cut their target price on shares of Alumis from $26.00 to $19.00 and set a “buy” rating for the company in a research report on Friday, February 7th. Oppenheimer started coverage on shares of Alumis in a research note on Thursday, January 30th. They set an “outperform” rating and a $32.00 price target on the stock. Cantor Fitzgerald restated an “overweight” rating on shares of Alumis in a research note on Thursday, November 14th. Finally, Robert W. Baird started coverage on shares of Alumis in a research note on Thursday, October 31st. They set an “outperform” rating and a $25.00 price target on the stock. Seven research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Buy” and an average price target of $26.57.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.